Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion

Prostate

Volumn 66, Issue 12, 2006, Pages 1311-1318

  Lu, Yi ^a,b   Cai, Zhong ^a,b   Galson, Deborah L ^a   Xiao, Guozhi ^a   Liu, Yulin ^c   George, Diane E ^a   Melhem, Mona F ^a   Yao, Zhi ^b   Zhang, Jian ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Cell proliferation; Invasion; Monocyte chemotactic protein 1; Prostate cancer

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CCL2 PROTEIN, HUMAN; CHEMOKINE RECEPTOR; CHROMONE DERIVATIVE; MONOCYTE CHEMOATTRACTANT PROTEIN 1 RECEPTOR; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE;

ADVANCED CANCER; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL ACTIVATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MONOCYTE; OSTEOBLAST; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL2; CHROMONES; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MORPHOLINES; NEOPLASM INVASIVENESS; OSTEOBLASTS; PROSTATIC NEOPLASMS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 33748375788     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20464     Document Type: Article

References (37)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;1:15-36.
2. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004;64:9209-9216.
3. Szostak MJ, Kyprianou N. Radiation-induced apoptosis: Predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncol Rep 2000;7:699-706.
4. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev 2001;12:313-335.
5. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999;103:773-778.
6. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999;154:1503-1512.
7. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837.
8. Reiland J, Furcht LT, McCarthy JB. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 1999;41:78-88.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
10. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006;66:124-134.
11. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000;6:2104-2119.
12. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, Jimenez-Baranda S, Garzon A, Lacalle RA, Harshman K, Ruiz A, Martinez AC. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003;198:1381-1389.
13. Lebrecht A, Hefler L, Tempfer C, Koelbl H. Serum cytokine concentrations in patients with cervical cancer: Interleukin-4, interferon-gamma, and monocyte chemoattractant protein-1. Gynecol Oncol 2001;83:170-171.
14. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A, Kainz C. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 1999;81:855-859.
15. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2004;99:1667-1674.
16. Vanderkerken K, Vande Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B. Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5 T multiple myeloma cells. Clin Exp Metastasis 2002;19:87-90.
17. Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003;88:855-862.
18. Johrer K, Janke K, Krugmann J, Fiegl M, Greil R. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res 2004;10:1901-1910.
19. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 2004;203:688-695.
20. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ, Taichman RS. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89:462-473.
21. Pen-one EE, Theoharis C, Mucci NR, Hayasaka S, Taylor JM, Cooney KA, Rubin MA. Tissue microarray assessment of prostate cancer tumor proliferation in African-American and white men. J Natl Cancer Inst 2000;92:937-939.
22. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974. J Urol 2002;167:953-958; discussion 959.
23. Babaian RJ, Troncoso P, Steelhammer LC, Lloreta-Trull J, Ramirez EI. Tumor volume and prostate specific antigen: Implications for early detection and defining a window of curability. J Urol 1995;154:1808-1812.
24. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-7474.
25. Mazzucchelli L, Loetscher P, Kappeler A, Uguccioni M, Baggiolini M, Laissue JA, Mueller C. Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am J Pathol 1996;149:501-509.
26. Chetcuti A, Margan S, Mann S, Russell P, Handelsman D, Rogers J, Dong Q. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate 2001;47:132-140.
27. Rahimi P, Wang CY, Stashenko P, Lee SK, Lorenzo JA, Graves DT. Monocyte chemoattractant protein-1 expression and monocyte recruitment in osseous inflammation in the mouse. Endocrinology 1995;136:2752-2759.
28. Kyriakides TR, Foster MJ, Keeney GE, Tsai A, Giachelli CM, Clark-Lewis I, Rollins BJ, Bornstein P. The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Am J Pathol 2004;165:2157-2166.
29. Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 2005;280:16163-16169.
30. Vaday GG, Hua SB, Peehl DM, Pauling MH, Lin YH, Zhu L, Lawrence DM, Foda HD, Zucker S. CXCR4 and CXCL12 (SDF-1) in prostate cancer: Inhibitory effects of human single chain Fv antibodies. Clin Cancer Res 2004;10:5630-5639.
31. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Silva LJ. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005;65:11001-11009.
32. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
33. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802-807.
34. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001;142:4795-4805.
35. Zi X, Singh RP, Agarwal R. Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 2000;21:2225-2235.
36. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000;141:2257-2265.
37. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-964.